Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B. Gordon, Peter Foley, James G. Krueger, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 475-486
Closed Access | Times Cited: 206

Showing 1-25 of 206 citing articles:

Antibodies to watch in 2022
Hélène Kaplon, Alicia M. Chenoweth, Silvia Crescioli, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 303
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B. Warren, Mark Lebwohl, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 142-152
Open Access | Times Cited: 279
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim Papp, Andrew Blauvelt, et al.
The Lancet (2021) Vol. 397, Iss. 10273, pp. 487-498
Closed Access | Times Cited: 216
Bimekizumab versus Adalimumab in Plaque Psoriasis
Richard B. Warren, Andrew Blauvelt, Jerry Bagel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 2, pp. 130-141
Open Access | Times Cited: 168
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Sophie Glatt, Gregor B. E. Jemec, Seth Forman, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 11, pp. 1279-1279
Open Access | Times Cited: 130
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 110
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease
Brunette Katsandegwaza, William Horsnell, Katherine A. Smith
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9344-9344
Open Access | Times Cited: 110
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F. Merola, Robert Landewé, Iain B. McInnes, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 38-48
Open Access | Times Cited: 107
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 4, pp. 515-526
Open Access | Times Cited: 70
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 43
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Immunological Reviews (2024) Vol. 322, Iss. 1, pp. 98-112
Open Access | Times Cited: 29
Real‐world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single‐center retrospective study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 5, pp. 649-658
Open Access | Times Cited: 22
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Kim Papp, Mark Weinberg, A. O. Morris, et al.
The Lancet (2021) Vol. 397, Iss. 10284, pp. 1564-1575
Closed Access | Times Cited: 95
The biological basis of disease recurrence in psoriasis: a historical perspective and current models
L. Puig, Antonio Costanzo, Ernesto J. Muñoz‐Elías, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 5, pp. 773-781
Open Access | Times Cited: 62
The Role of IL-17 Cytokines in Psoriasis
Megan Mosca, Julie Hong, Edward Hadeler, et al.
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 409-418
Open Access | Times Cited: 61
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Hakim Ben Abdallah, Claus Johansen, Lars Iversen
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 83-97
Open Access | Times Cited: 58
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
M. Masson Regnault, Jason Shourick, Fatma Jendoubi, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 433-447
Open Access | Times Cited: 48
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 7, pp. 735-735
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top